The experience and perspective to fulfill the promise.
Meet our executive leaders and directors.
Todd C. Brady, M.D., Ph.D.
Chief Executive Officer, President & Director
Dr. Brady has served as our President and Chief Executive Officer since January of 2012 and as a member of our board of directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc. and Spring Bank Pharmaceuticals, Inc., both of which are publicly traded healthcare companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
David J. Clark, M.D., M.R.C.P., A.F.P.M.
Chief Medical Officer
David J. Clark, M.D. has served as our Chief Medical Officer since January 2016. He has approximately 19 years of global industry experience in both pharmaceutical firms and biotechnology companies based in the United States and Europe. Prior to joining Aldeyra, Dr. Clark served as the Chief Medical Officer of Wilson Therapeutics, a privately-held biotechnology company developing novel pharmaceuticals to treat Wilson Disease, a rare autosomal recessive disorder of copper metabolism, from 2013 to 2015. Prior to that, from September 2011 to February 2013, he served as the Senior Vice President of Translational Medicine of TransTech Pharma, LLC, a privately held pharmaceutical company focused on the discovery and development of human therapeutics across a wide range of indications in several therapeutic areas, including metabolic, neuroscience, respiratory, ophthalmology and oncology. Previously, he held the role of Chief Medical Officer at NormOxys Inc., a privately held biotechnology company focused on the development of a new class of small molecule drugs for the treatment of oncology, cardiovascular and neuroscience indications. Dr. Clark has also held clinical leadership positions at Pfizer Inc. from 2001 to 2009 and at GlaxoSmithKline plc from 1997 to 2001. Dr. Clark received his medical degree from the University of Edinburgh, trained in internal medicine and conducted respiratory medicine academic research in the UK before moving into pharmaceutical industry research.
Stephen Tulipano, CPA
Chief Financial Officer
Stephen Tulipano has served as our Chief Financial Officer since June 2014. He has 30 years of accounting and financial experience, of which 17 years were focused on the pharmaceutical industry. Most recently, he held positions at Three Tulips Inc., an accounting and management advisory services firm, where he provided full-time accounting services and financial management counsel from September 2010 to June 2014. Prior to that, from April 2006 to July 2010, he served as Chief Financial Officer, Treasurer and Secretary of Javelin Pharmaceuticals where he helped lead the company through its acquisition by Hospira in 2010. Previously, he held the role of Director of Corporate Accounting at Biogen Idec. He has also held several accounting roles both within companies and accounting firms. Mr. Tulipano holds a B.S. in Business Administration and Accounting from Salem State College and an M.B.A. in Finance from the Sawyer School of Management at Suffolk University. He is also a Certified Public Accountant.
David B. McMullin, M.B.A.
SVP, Corporate Development and Strategy
David McMullin has served as our head of Corporate Development and Strategy since May of 2018. He has over 20 years of experience leading business development, strategic planning, and commercial launch and operations in the biopharmaceutical industry. Prior to joining Aldeyra, Mr. McMullin was Group Vice President, U.S. Internal Medicines franchise at Shire plc where he led sales, marketing, and business operations for the rare disease and specialty products business unit. Prior to that Mr. McMullin was Vice President of the Commercial Center of Excellence at Shire, responsible for commercial operations worldwide. Prior to joining Shire, Mr. McMullin was the Vice President of Global Supply Chain and Strategy at Novartis Vaccines and Diagnostics (now part of GlaxoSmithKline plc), where he led a successful operational turnaround followed by an asset swap divestiture between Novartis AG and GlaxoSmithKline plc. Mr. McMullin previously held multiple leadership and management positions in marketing, sales, and corporate strategy at multiple different divisions of Novartis AG. Before joining Novartis, he worked at Charles River Associates, Inc. Mr. McMullin received a Master of Business Administration degree from Harvard University, and a Bachelor of Science degree from Brigham Young University.
BOARD OF DIRECTORS
Richard H. Douglas, Ph.D.
Chairman of the Board
Dr. Douglas has served on our board of directors since September 2016. Dr. Douglas is the former Senior Vice President, Corporate Development of Genzyme Corporation. Since 2011, Dr. Douglas has been an independent consultant and advisor at Red Sky Partners LLC. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly traded clinical-stage vaccine company, and he also serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology.
Martin J. Joyce
Mr. Joyce has served as member of our board of directors since October 2013. Mr. Joyce’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
Gary Phillips, M.D.
Dr. Phillips has served as Executive Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc since October 2013 and has been a member of our board of directors since May 2009. He was President of Reckitt Benckiser Pharmaceuticals, Inc. from 2011 to 2012. He served as President of U.S. Surgical and Pharmaceuticals at Bausch & Lomb Incorporated from 2002 to 2008. Dr. Phillips has also held executive roles at Merck Serono SA from 2008 to 2011, Novartis Corporation from 2000 to 2002, and Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.) from 1999 to 2000. He was most recently Head of Global Health & Healthcare Industries at the World Economic Forum in Geneva from January 2012 to September 2013. Dr. Phillips was also healthcare strategy managing consultant at Towers Perrin from 1997 to 1999, and practiced as a general medicine clinician/officer in the US Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine in 1992, an MBA from the Wharton School in 1991, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences in 1987. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.
Jesse I. Treu, Ph.D.
Dr. Treu has served on our board of directors since June 2013. Dr. Treu has been a Partner of Domain Associates, L.L.C. since its inception in 1985. He has been a director of over 35 early-stage healthcare companies. Dr. Treu currently serves as a member of the boards of directors of Sebacia, Inc., Tandem Diabetes Care, Inc., Veracyte, Inc. and Xagenic, Inc. He has also served as a founder, president and chairman of numerous venture-stage companies. From December 2009 to July 2016, he served as a member of the board of directors of Afferent Pharmaceuticals, Inc., a biotechnology company subsequently acquired by Merck & Co. He also served as a member of the board of directors of RightCare Solutions, Inc. from August 2013 to December 2015. Prior to the formation of Domain Associates, Dr. Treu had twelve years of experience in the healthcare industry. He was Vice President of the predecessor organization to The Wilkerson Group and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, Inc., a pioneer in computer image processing for cardiology. Previous to that, Dr. Treu led new product development and marketing planning for immunoassay and histopathology products at Technicon Instruments Corporation, which is now part of Siemens Medical Solutions Diagnostics. Dr. Treu began his career with General Electric Company in 1973, initially as a research scientist developing thin film optical sensors for immunoassay testing, and later serving on the corporate staff with responsibility for technology assessment and strategic planning. Dr. Treu received his B.S. in Physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.
Ben Bronstein, M.D.
Dr. Bronstein has served as a member of our board of directors since 2010, and from 2010 to 2011 served as Chief Executive Officer of Aldeyra, then known as Neuron Systems. Dr. Bronstein is an independent consultant to life science companies at Cold Spring Venture Advisors, where he has been the sole proprietor from September 2009 to date. He has spent the past 27 years in entrepreneurial roles in life science companies and venture capital firms. Most recently, from January 2014 to August 2015, he was Chief Medical Officer of Stealth BioTherapeutics, a privately held company developing pharmaceuticals for serious diseases associated with mitochondrial dysfunction, prior to which he was a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School from January 2013 to July 2014. Dr. Bronstein has founded or held senior management positions at several venture-backed life science firms, including OKPO Health, a life science company developing human therapeutics and diagnostics, from May 2008 to November 2009, and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma, from November 2006 to May 2008. He has also held senior roles in life science investment firms including as a founder and senior vice president of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc., from January 2012 to December 2012. Dr. Bronstein has served on the boards of directors of several privately held life science companies. He is also a member of the Weill Cornell Medical College Faculty Industry Council. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He received his M.D. and M.B.A. from Boston University.
Neal Walker, D.O.
Dr. Walker has served on our board of directors since June 2013. Dr. Walker is the President and Chief Executive Officer and a director at Aclaris Therapeutics, Inc., a publicly-traded dermatological drug development company. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Ltd); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker currently is on the Board of Directors of Aclaris Therapeutics, Inc., Sebacia, Inc. and Follica, Inc. (Executive Chairman). Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University. He is a board-certified dermatologist.